Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SSS11 (Pegsiticase) in Healthy Volunteers
NCT03388515Phase 1Unknown
- Sponsor
- 3SBio
- Start
- Oct 2017
- Primary completion
- Jul 2019
- Modality
- Therapeutic Enzymes, PEGylated Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pegadricase in gout (5 arms), sponsored by 3SBio. Primary endpoints: Incidence of adverse events at 4 weeks and Maximum Tolerable Dose at 4 weeks. Status: unknown.
02
Drugs
pegadricase
03
Conditions
gout
Beyond the preview
Go deeper on NCT03388515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03388515.